Protein Degradation Leader Nurix Prepares First Clinical Trial
Company Claims Unique Protein Modulation Potential
After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.
You may also be interested in...
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.